Carson Tahoe Health First In Northern Nevada To Offer Only FDA-Approved, Naturally Dissolving Heart Stent
Courtesy of Carson Tahoe Health
CARSON CITY, Nev. — Coronary artery disease (CAD) patients in Northern Nevada now have a new treatment option that literally disappears over time, only at Carson Tahoe Health.
Michelle Joy, Chief Operating Officer, recently announced that Carson Tahoe is among the first in the country – and the only provider in the region – to offer the latest generation of state-of-the-art cardiology technology, Absorb.
The revolutionary Absorb bioresorbable vascular scaffold is a significant advancement in the treatment of CAD, which affects 15 million Americans and remains the leading cause of death worldwide. Carson Tahoe Health successfully placed the Absorb stent for the first time earlier this month and is looking forward to changing lives with this exciting technology.
“Absorb is a game-changing therapy for coronary artery disease,” said Michelle Joy, Vice President and COO of Carson Tahoe Health. “This innovative technology provides the ability to repair a patient’s artery while reducing long-term complications. This method encourages healing while promoting and supporting the natural functions of the heart.”
Traditionally, metal stents have served as permanent implants, and been a patient’s only treatment option. Absorb is made of naturally dissolving materials, similar to dissolving sutures. Like metallic drug-eluding stents, Absorb opens and treats a patient’s blocked artery, but then fully dissolves after about three years, leaving no metal behind. The restored artery can flex and pulse naturally, promoting proper healing and reducing the risk of future blockages. Absorb can also make it easier for doctors to perform additional interventions in
the case of another cardiac event.
“We are very excited to be the first ones to offer this leading-edge Absorb therapy – one of the world’s most advanced cardiac treatments – in Northern Nevada” added Joy.
Carson Tahoe Health offers a variety of advanced cardiac technologies and treatments, including traditional metal stents, drug-alluding stents, and open-heart surgery, among others. While certain complex and hardened blockages may be better served by regular
metallic stents, Absorb has proven to be beneficial for patients with their first CAD presentation. Patients with CAD should consult their cardiologist to discuss the best treatment option based on their unique needs.
To learn more about Absorb and other innovative cardiac treatments at Carson Tahoe Health, visit www.carsontahoe.com/absorb.
About Carson Tahoe Health
Carson Tahoe Health System is a local, not-for-profit healthcare system with 240 licensed acute care beds. Serving a population of over 250,000, CTH features two hospitals, two urgent cares, an emergent care center, outpatient services and a provider network with 20 regional locations. The system is headquartered on a beautiful master planned 80-acre medical campus nestled among the foothills of the Sierra Nevada in North Carson City. As the system’s cornerstone, Carson Tahoe Regional Medical Center (CTRMC), voted 5th most beautiful hospital in the nation, was the first Baby-Friendly designated hospital in Nevada. Also included on the campus is Carson Tahoe Sierra Surgery, the 15-bed boutique elective surgery arm of CTRMC, and Carson Tahoe Cancer Center, an affiliate of Huntsman Cancer
Institute, University of Utah. For more information, go to www.carsontahoe.com.